Online citations, reference lists, and bibliographies.
← Back to Search

Role Of P-glycoprotein In Drug Disposition.

Y. Tanigawara
Published 2000 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
P-glycoprotein (Pgp), which is coded by human MDR1 (multidrug resistance) gene, is an energy-dependent efflux pump that exports its substrates out of the cell. Human Pgp is present not only in tumor cells but also in normal tissues including the kidney, liver, small and large intestine, brain, testis, and adrenal gland, and the pregnant uterus. This tissue distribution indicates that Pgp plays a significant role in excreting xenobiotics and metabolites into urine and bile and into the intestinal lumen, and in preventing their accumulation in the brain. The roles of Pgp in drug disposition include a urinary excretion mechanism in the kidney, a biliary excretion mechanism in the liver, an absorption barrier and determinant of oral bioavailability, and the blood-brain barrier that limits the accumulation of drugs in the brain. The inhibition of the transporting function of Pgp can cause clinically significant drug interactions and can also increase the penetration of drugs into the brain and the accumulation of drugs in the brain. Digoxin is a typical substrate for Pgp, which regulates the renal tubular secretion and brain distribution of digoxin. At present, potent Pgp inhibitors are being investigated in clinical trials aimed at overcoming the intrinsic or acquired multidrug resistance of human cancers. The clinical application of these Pgp inhibitors should take into consideration the physiologic function of pgp.
This paper references
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
Franz Thiebaut (1987)
P-Glycoprotein, a gatekeeper in the blood-brain barrier.
Schinkel (1999)
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
A. Schinkel (1996)
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
C. Cordon-Cardo (1989)
A general pattern for substrate recognition by P-glycoprotein.
A. Seelig (1998)
Pharmacological insights from P-glycoprotein knockout mice.
A. Schinkel (1998)
Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease
J. J. Smit (1993)
Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney.
N. Okamura (1993)
Effect of optokinetic stimulation on the H reflex in humans.
M. Hoshiyama (1994)
Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein
N. Kusunoki (1998)
Relationship between expression level of P-glycoprotein and daunorubicin transport in LLC-PK1 cells transfected with human MDR1 gene.
K. Tanaka (1997)
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.
A. Schinkel (1997)
P‐glycoprotein‐mediated transcellular transport of MDR‐reversing agents
T. Saeki (1993)
Human P-glycoprotein transports cyclosporin A and FK506.
T. Saeki (1993)
Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.
K. Ueda (1992)
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
A. Schinkel (1994)
The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation.
K. Uéda (1987)
Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).
Y. Tanigawara (1992)
Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney.
R. Hori (1993)
Treatment of Refractory and Relapsed Acute Myelogenous Leukemia With Combination Chemotherapy Plus the Multidrug Resistance Modulator PSC 833 (Valspodar)
R. Advani (1999)

This paper is referenced by
Possible association of ABCB 1 : c . 3435 T > C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment-a pilot study
A. Sałacka (2014)
Studies on pharmacokinetic mechanism of phenytoin resistance in refractory epilepsy.
Mingliang Lai (2013)
In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms
M. Schaefer (2006)
Is P‐glycoprotein Involved in Amyloid‐β Elimination Across the Blood–Brain Barrier in Alzheimer's Disease?
S. Ohtsuki (2010)
Safety aspects of HIV-protease inhibitors
J. Dieleman (2002)
Oral antifungal drug interactions: a mechanistic approach to understanding their cause.
H. Katz (2003)
Hesperetin Glucuronide, a Photoprotective Agent Arising from Flavonoid Metabolism in Human Skin Fibroblasts¶
A. Proteggente (2003)
Fluvastatin in the Treatment of Dyslipidemia Associated with Chronic Kidney Failure and Renal Transplantation
A. Corsini (2005)
Investigating the role of potential genetic markers that can predict risk for steroid refractory inflammatory bowel disease
A. Krupoves (2011)
ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer
M. Panczyk (2009)
The conformation and dynamics of P‐glycoprotein in a lipid bilayer investigated by atomic force microscopy
K. Sigdel (2018)
Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding
A. Seelig (2006)
Addition of TPGS to folate-conjugated polymer micelles for selective tumor targeting.
H. Zhao (2009)
Pharmacokinetics and Pharmacodynamics of Intravenous Inotropic Agents
L. Lehtonen (2004)
Metabolism and Renal Elimination of Gaboxadol in Humans: Role of UDP-Glucuronosyltransferases and Transporters
X. Chu (2008)
Effect of benzo[a]pyrene on P-glycoprotein-mediated transport in Caco-2 cell monolayer.
N. Sugihara (2006)
Variant genotypes of MDR1 C3435T increase the risk of leukemia: evidence from 10 case–control studies
Xifeng Qian (2012)
Introduction to Drug-Drug Interactions
M. Pai (2018)
Immunocytochemical studies on the distribution pattern of daunomycin in rat gastrointestinal tract
K. Ohara (2007)
ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research
G. Leschziner (2007)
Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects
I. Cascorbi (2001)
Pharmacogenomics and Personalized Medicine in the Treatment of Human Diseases
H. Lee (2009)
Investigation of ABCB1 1236 and 2677 SNPs in patients with peptic ulcer
M. Żebrowska (2012)
"In silico" prediction of blood-brain barrier permeation and P-glycoprotein activity
Grégori Gerebtzoff (2008)
Variações interindividuais na farmacocinética clínica de cardiotônicos
F. C. Souza (2013)
Elevated International Normalized Ratio values in a patient receiving warfarin and ceftaroline.
Nada M. Farhat (2016)
Potential P-glycoprotein-mediated drug-drug interactions of antimalarial agents in Caco-2 cells.
E. F. Oga (2012)
Hepatic Uptake and Excretion of (–)-N-{2-[(R)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans
Ken-Ichi Umehara (2008)
ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis
J. Su (2015)
Variability in response to cardiovascular drugs.
E. E. El Desoky (2006)
Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
Hairong Huo (2010)
Principles and Clinical Application of Assessing Alterations in Renal Elimination Pathways
S. Tett (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar